Korea Investment CORP Sells 67,955 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Korea Investment CORP trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 32.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 141,077 shares of the medical research company's stock after selling 67,955 shares during the quarter. Korea Investment CORP owned approximately 0.08% of IQVIA worth $27,723,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth about $33,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. lifted its stake in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Versant Capital Management Inc lifted its stake in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA during the 4th quarter worth approximately $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 2.7 %

IQVIA stock traded down $4.79 during trading hours on Tuesday, reaching $171.51. 602,879 shares of the company's stock were exchanged, compared to its average volume of 1,468,376. IQVIA Holdings Inc. has a twelve month low of $169.37 and a twelve month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm's 50 day simple moving average is $192.73 and its 200 day simple moving average is $205.61. The firm has a market capitalization of $30.24 billion, a PE ratio of 22.88, a PEG ratio of 1.99 and a beta of 1.50.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on IQV shares. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Barclays dropped their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Finally, BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.